Cutaneous melanoma · line 1 · Pembrolizumab adjuvant (resected stage III/IV melanoma; KEYNOTE-054)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-PEMBRO-ADJUVANT-MELANOMA`

ID	`IND-MELANOMA-ADJUVANT-PEMBRO-STAGE-III`
Type	Indication
Status	reviewed 2026-04-30 \| pending_clinical_signoff
Diseases	`DIS-MELANOMA`
Sources	`SRC-CHECKMATE-238-WEBER-2017` `SRC-ESMO-MELANOMA-2024` `SRC-KEYNOTE-054-EGGERMONT-2018` `SRC-NCCN-MELANOMA-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Standard-track adjuvant indication for resected stage III melanoma. Surfaced by curated case patient_melanoma_adjuvant_pembro_stage_iii.json (KB drift note: no adjuvant Stage III indication or algorithm existed; metastatic-1L algorithm was incorrectly resolving for resected disease). Wiring into a future ALGO-MELANOMA-ADJUVANT is engine work and out of scope for this commit. Pairs with KEYNOTE-006 metastatic-1L pembro mono indication (same drug, different stage / intent).

Used By

Algorithms

ALGO-MELANOMA-ADJUVANT-1L - ALGO-MELANOMA-ADJUVANT-1L
ALGO-MELANOMA-METASTATIC-1L - ALGO-MELANOMA-METASTATIC-1L

Red flag

RF-MELANOMA-STAGE-III-RESECTED - Resected stage III cutaneous melanoma — adjuvant-eligible biology (positive sentinel-lymp...